Chinecancer biotech BeiGene prices IPO at $24, the high end of the rangse e

BeiGene, a Chinese biotech developing cancer therapies for China and global markets, raised $158 million by offering 6.6 million shares at $24, the high end of the range of $22 to $24. BeiGene plans to list on the Nasdaq under the symbol BGNE. Goldman Sachs, Morgan Stanley and Cowen & Company acted as lead managers on the deal.

 

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.